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OBJECTIVES: Breast cancer is the most common cancer in women, representing
16% of all female cancers. According to American Cancer Society (ACS), long-term
cancer survival is defined as more than five years of survivorship since diagnosis,
with approximately 2.5million breast cancer survivors (BCS) in 2006. The long-term
effects from breast cancer and its treatment have been shown to have positive and
negative effects on both recovery and survivors’ quality of life (QoL). The purpose of
the study is to identify QoL instruments that have been validated in long-term BCS
and to review the studies that have used the QoL instruments in this population.
METHODS: A systematic literature search was conducted from January 1990 to
October 2010 using electronic databases. Instruments validated in BCS were
included in the review. In addition, QoL studies in long-term BCS using the
validated instruments were reviewed. The search was limited to studies using
English language. Studies of BCS of less than five years after initial diagnosis,
any clinical or review studies were excluded. RESULTS: A total of 12 QoL instru-
ments were identified (10 disease-specific, 2 condition-specific). According to
the QoL framework proposed by Ferrell and colleagues, three identified instru-
ments (Quality of Life-Cancer Survivors, Quality of Life in Adult Cancer Survi-
vors Scale (QLACS), and Quality of Life Index-Cancer Version) evaluated all four
domains (physical, psychological, social, and spiritual) of QoL. A review of the
psychometric evaluation showed that QLACS has acceptable reliability, validity,
and responsiveness in long-term BCS. The review also yielded 19 studies that
used the QoL instruments. The study results indicated that age-groups, ethnic-
ity, and type of treatment influenced different aspects of QoL. CONCLUSIONS:
There is a significant impact of breast cancer on long-term BCS’s QoL. The
review can help researchers and clinicians select the most appropriate instru-
ments to assess the changes in QoL in BCS.
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OBJECTIVES: This study assessed willingness to pay (WTP) to avoid chemotherapy
induced nausea and vomiting (CINV) among 303 cancer patients. It also assessed
differences in WTP by patient-level characteristics.METHODS:WTP was assessed
using results from a choice-based conjoint survey. Patients viewed 25 scenarios
each involving 2 descriptions of CINV and indicated which they preferred. Each
scenario represented a combination of levels from 8 attributes (e.g., chance of
nausea). Preference for levels within attributes and WTP were assessed using a
probit model. Interaction terms were added to determine if strength of preference
andWTP differed by demographics, disease characteristics, treatment history, and
history of CINV. RESULTS: Patients were 79% Caucasian and 16%African American
with amean age of 59.35 years (range26-86). Forty percent had breast cancer, 35%
lung cancer, and 25% colorectal cancer. Sixty-eight percent were on HEC/MEC, 22%
had been on HEC/MEC in the last 6 months, and 10% were chemotherapy naïve.
Patientswerewilling to pay to avoidmore than 30% chance of nausea (WTP to avoid
50%: $42.61, p  0.0004; WTP to avoid 70%: $49.57, p  0.0002), more than 1 day of
nausea (2-5 days: $62.80, p 0.0001; 5 days: $107.50, p 0.0001), nausea that
impaired functioning (some activities: $103.87, p .0001; self-care: $116.32, p
0.0001), vomiting more than 1-2 times/day (3-5 times/day: $45.52, p 0.0001; 5
times/day: $52.10, p 0.0001), vomiting longer than a half-day (1 day: $20.12, p 
0.0162; 2-5 days: $133.05, p .0001), and dehydration not treatable at home (clinic
visit: $61.26, p 0.0001; hospital visit: $109.47, p 0.0001). WTP varied by income,
primary diagnosis, disease stage, ECOG performance status, HEC/MEC group, and
whether patients had worked while on chemotherapy. CONCLUSIONS: The study
identifies substantial group differences in preference andWTP that could be incor-
porated into the management of CINV.
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IMPACT OF GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND
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OBJECTIVES: During 2009-2010 major healthcare reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the US,
AMNOG in Germany, HSPT in France, KVG in Switzerland and NHS proposed re-
form in the UK. These reforms have major implications on pricing, market access
and HEOR strategy for drug and device products. METHODS: To understand the
implications of these trends, we analyzed 2009-2010 reform bills and proposed
changes worldwide. Additionally, we interviewed public and private payers, key
opinion leaders and payer-influencers to understand implications of these reforms
on drug and device manufacturers. RESULTS: The global healthcare landscape is
expected to undergo significant change during 2011-2015. In the US, government
will play increased role as a single payer, especially with–Medicare, Medicaid and
CHIP programs– whichwill cover 114million Americans, at a cost of $784 billion. In
Germany, AMNOG bill marked the end of free drug pricing and would lead to
increased insurance premiums (now 15.5% of wages). In the UK, NHS has proposed
to replace PCTs with 500-1000 GP-led consortia and use value-based pricing for
expensive drugs and devices. Overall, payers view that in the future, health eco-
nomic assessments would play critical role in pricing, coverage and reimburse-
ment of branded products. CONCLUSIONS: This analysis shows that global health-
care landscape is expected to undergo significant change during 2011-2015.
Discussions with payers, KOLs and payer-influencers highlights increased impor-
tance of HEOR data in the future.
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OBJECTIVES: The treatment of bevacizumab in patients with metastatic colorectal
carcinoma, in combination with fluoropyrimidine-based chemotherapy, is pur-
chased by the NHS according to an agreement issued between AIFA and the man-
ufacturer. The agreement includes the enrollement of patient in a monitoring reg-
istry and a cost-sharing scheme, based on 50% discounts of initial therapy cycles
for all eligible patients and the refund of cost of doses exceeding the total dosage of
11.000 mg for each year of treatment (capping-dosage). This study is aimed at the
economic evaluation of the financial agreement on the basis of evidences collected
by the Registry. METHODS: Data were collected for patients enrolled in 2009,
lock-on database at November 30, 2010. Data on baseline characteristics were ana-
lysed for eligible patients, whereas duration treatment, dosage and financial out-
come were collected for patients whose therapy was completed. RESULTS: The
Registry enrolled 4602patients. Baselinepatient age included52.8%patients aged 65
years, 24.4% of patients with an ECOG performance status 1. At database lock,
2667 (57.9%) patients had completed the treatment, 66.3% for progression disease,
2.8% patients had died, 13.3% for clinical decision and 4.7% for the medicine toxic-
ity, 13.3% for non-relatedmedicine causes. The dosage of 5-mg/kg every two-weeks
was themost used, both in first (84.5%) and in second-line (81.9%).Median-duration
therapy was 160-day (9 cycles). Data on safety were consistent with available evi-
dences. The cost-sharing-agreement financial outcome produced was a median
discount of 12.2% of therapy costs reimbursed by NHS: cost-sharing accounting for
12.1% and capping-dosage for 0.1%. CONCLUSIONS: The implementation of the
cost-sharing scheme supported early patient access to the treatment, introducing
bevacizumab in Italy at global-reference-price, with an effective overall discount
produced essentially by the cost-sharing tool, linked to dosage and number of total
doses required. The Registry also facilitated the collection of utilization evidences
from real clinical world, improving the appropriate use and increasing efficiency.
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OBJECTIVES: Identify differences in diagnosis and treatment of commercially in-
sured White and African American women with newly diagnosed breast cancer.
METHODS:Weconducted a retrospective, observational analysis of a Southeast US
health plan’s administrative claims data linked to Georgia Comprehensive Cancer
Registry (GCCR) data from 1/1/04 to 12/31/07 on newly diagnosed African American
and White breast cancer patients. Medical and pharmacy utilization data were
obtained from the claims. Cancer characteristics such as diagnosis date, Estrogen/
Progesterone Receptor (ER/PR) status and race were obtained from the GCCR. Pa-
tients without race data or coded as other races were removed for a final sample
size of 1,497. Descriptive analyses were conducted with t-tests for continuous vari-
ables and chi-square for categorical variables. Multiple logistic regression deter-
mined factors associated with lower use of anti-estrogen therapy among African
Americanwomen. RESULTS:When comparing African American toWhitewomen,
African American women were younger at diagnosis (mean age: 50 vs. 53 years,
p0.01), were diagnosed at later stages of breast cancer (Stage 0: 20% vs. 21%; Stage
1: 30% vs. 38%; Stage 2: 30% vs. 27%; Stage 3: 10% vs. 7%; Stage 4: 5% vs. 1% and
unknown stage: 6% vs. 5%, p0.01), and had a longer time to treatment (surgery: 57
vs. 42 days, p0.01; radiation: 177 vs. 138 days, p0.01; anti-estrogen therapy: 211
vs. 180 days, p0.07). Amongwomenwhowere ER/PR-positive,Whitewomenwere
more than twice as likely as African American women to be treated with anti-
estrogen therapy (OR  2.24, 95% CI: 1.46-3.43), after controlling potential
confounders. CONCLUSIONS: This study demonstrates that diagnosis and treat-
ment of breast cancer in African American women differ from that of White
womendespite having access to commercial insurance.We also illustrate that data
linkages provide quick and efficient methods for assessment of cancer treatment
patterns and identification of targets for further research.
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HEALTH CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF
METASTATIC AND RECURRENT LOCALLY-ADVANCED HEAD AND NECK
CANCER PATIENTS
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OBJECTIVES: To assess healthcare resource utilization and economic burden asso-
ciated with metastatic and recurrent, locally-advanced head and neck cancer
(HNC). METHODS: Administrative claims from Medicare- and privately-insured
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